[Lymphoma].
作者信息
Mohar A, Sobrevilla-Calvo P, Velasquez W S
机构信息
Instituto Nacional de Cancerología, University of Texas, Galveston, Texas, USA.
出版信息
Rev Invest Clin. 1997 May;49 Suppl 1:56-63.
PMID:9380990
Abstract
摘要
相似文献
1
[Lymphoma].
Rev Invest Clin. 1997 May;49 Suppl 1:56-63.
2
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x.
3
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Br J Haematol. 2005 Aug;130(3):363-72. doi: 10.1111/j.1365-2141.2005.05603.x.
4
Hodgkin's disease.
Rev Invest Clin. 1994 Apr;Suppl:73-83.
5
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Haematologica. 2002 Aug;87(8):816-21.
6
Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
Bone Marrow Transplant. 2001 Nov;28(9):813-20. doi: 10.1038/sj.bmt.1703255.
7
Treatment of relapses in aggressive non Hodgkin's lymphoma.
Bull Cancer. 2004 Jul-Aug;91(7-8):E261-73.
8
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.
9
Minimal residual disease: lessons to be learned from malignant lymphoma.
Bone Marrow Transplant. 1990 Jul;6 Suppl 1:73-5.
10
[Autologous transplant with BEAM protocol in lymphoma].
Sangre (Barc). 1997 Apr;42 Suppl 1:46-9.
Zotero 插件